Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 3, 2009, Pages 552-559

  Minutolo, Roberto ^a   Chiodini, Paolo ^a   Cianciaruso, Bruno ^b   Pota, Andrea ^b   Bellizzi, Vincenzo ^c   Avino, Deborah ^a   Mascia, Sara ^a   Laurino, Simona ^a   Bertino, Valerio ^a   Conte, Giuseppe ^a   De Nicola, Luca ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Clinical Laboratory Analysis   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DEATH; DRUG RESPONSE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; RETROSPECTIVE STUDY; SURVIVAL RATE; AGED; BLOOD; CLINICAL TRIAL; ITALY; KIDNEY DISEASE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; ITALY; KIDNEY DISEASES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 66149111405     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04380808     Document Type: Article

References (38)

1. El Nahas AM, Bello AK: Chronic kidney disease: The global challenge. Lancet 365: 331-340, 2005 (Pubitemid 40139112)
2. US Department of Health and Human Services: Healthy People 2010, 2nd Ed., Washington, DC: US Government Printing Office, 2000
3. Levin A, Djurdjev O, Duncan J, Rosenbaum D, Werb R: Haemoglobin at time of referral prior to dialysis predicts survival: An association of haemoglobin with long-term outcomes. Nephrol Dial Transplant 21: 370-377, 2006 (Pubitemid 43159990)
4. Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W: Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: The ARIC Study. Kidney Int 64: 610-615, 2003 (Pubitemid 36871933)
5. Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ: Kidney function and anemia as risk factors for coronary heart disease and mortality: The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 151: 492-500, 2006 (Pubitemid 43144756)
6. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE: Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 69: 560-564, 2006 (Pubitemid 43164450)
7. Iseki K, Ikemiya Y, Iseki C, Takishita S: Haematocrit and the risk of developing end-stage renal disease. Nephrol Dial Transplant 18: 899-905, 2003 (Pubitemid 36592530)
8. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD: Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 66: 1131-1138, 2004 (Pubitemid 39121019)
9. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt K, Horl WH, Macdougall IC, Macleod A, Wiecek A, Cameron S: Revised European Best Practice Guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 19 [Suppl 2]: 1-47, 2004 (Pubitemid 29401692)
10. National Kidney Foundation: K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47 [Suppl 3]: S1-S146, 2006
11. Horl W, Macdougall IC, Rossert J, Rutkowski B, Wauters JP, Valderrabano F: Predialysis survey on anemia management: Patient referral. Am J Kidney Dis 41: 49-61, 2003 (Pubitemid 36043351)
12. De Nicola L, Minutolo R, Chiodini P, Zamboli P, Zoccali C, Castellino P, Donadio C, Strippoli M, Casino F, Giannattasio M, Petrarulo F, Virgilio M, Laraia E, Di Iorio BR, Savica V, Conte G, TArget Blood Pressure LEvels in Chronic Kidney Disease (TABLE in CKD) Study Group: Global approach to cardiovascular risk in chronic kidney disease: Reality and opportunities for intervention. Kidney Int 69: 538-545, 2006
13. Minutolo R, Sasso FC, Chiodini P, Cianciaruso B, Carbonara O, Zamboli P, Tirino G, Pota A, Torella R, Conte G, De Nicola L: Management of cardiovascular risk factors in advanced type 2 diabetic nephropathy: A comparative analysis in Nephrology, diabetology and primary care settings. J Hypertens 24: 1655-1661, 2006 (Pubitemid 44162469)
14. Hsu CY, McCulloch CE, Curhan GC: Iron status and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol 13: 2783-2786, 2002
15. Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, Bommer J, Cruz JM, Kerr PG, Mendelssohn DC, Held PJ, Port FK: Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44: 94-111, 2004 (Pubitemid 38880932)
16. Rasu RS, Manley HJ, Crawfordl T, Balkrishnan R: Undertreatment of anemia in patients with chronic kidney disease in the United States: Analysis of national outpatient survey data. Clin Ther 29: 1524-1534, 2007
17. Fishbane S, Berns JS: Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 68: 1337-1343, 2005 (Pubitemid 43246455)
18. Ebben JP, Gilbertson DT, Foley RN, Collins AJ: Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 1: 1205-1210, 2006
19. Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ: Hemoglobin level variability: Associations with mortality. Clin J Am Soc Nephrol 3: 133-138, 2008
20. Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI: Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 18: 3164-3170, 2007
21. De Nicola L, Conte G, Chiodini P, Cianciaruso B, Pota A, Bellizzi V, Tirino G, Avino D, Catapano F, Minutolo R: Stability of target hemoglobin levels during the first year of epoetin treatment in CKD patients. Clin J Am Soc Nephrol 2: 938-946, 2007
22. Fishbane S, Berns JS: Evidence and implications of hemoglobin cycling in anemia management. Nephrol Dial Transplant 22: 2129-2132, 2007 (Pubitemid 47244687)
23. Bailie GR, Eisele G, Liu L, Roys E, Kiser M, Finkelstein F, Wolfe R, Port F, Burrows-Hudson S, Saran R: Patterns of medication use in the RRI-CKD study: Focus on medications with cardiovascular effects. Nephrol Dial Transplant 20: 1110-1115, 2005 (Pubitemid 40862099)
24. Patwardhan MB, Samsa GP, Matchar DB, Haley WE: Advanced chronic kidney disease practice patterns among nephrologists and non-nephrologists: A database analysis. Clin J Am Soc Nephrol 2: 277-283, 2007
25. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, Moskowitz MA: Inadequate management of blood pressure in a hypertensive population. N Engl J Med 339: 1957-1963, 1998
26. Berlowitz DR, Ash AS, Hickey EC, Glickman M, Friedman R, Kader B: Hypertension management in patients with diabetes: The need for more aggressive therapy. Diabetes Care 26: 355-359, 2003 (Pubitemid 36929055)
27. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM: Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 47: 345-351, 2006 (Pubitemid 43740273)
28. Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, Miller CD, Ziemer DC, Barnes CS: Clinical inertia. Ann Intern Med 135: 825-834, 2001
29. Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, Villa G, Van Vlem B, McMahon AW, Kerloëguen C, Beyer U, STRIATA Study Investigators: Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: Results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 23: 3654-3661, 2008
30. Matthews JN, Altman DG, Campbell MJ, Royston P: Analysis of serial measurements in medical research. BMJ 300: 230-235, 1990 (Pubitemid 20045528)
31. Di Iorio BR, Minutolo R, De Nicola L, Bellizzi V, Catapano F, Iodice C, Rubino R, Conte G: Supplemented very low protein diet ameliorates responsiveness to erythropoietin in chronic renal failure. Kidney Int 64: 1822-1828, 2003
32. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method for classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 40: 373-383, 1987 (Pubitemid 17055592)
33. McGraw KO, Wong SP: Forming inferences about some intraclass correlation coefficients. Psychol Methods 1: 30-46, 1996
34. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39 [Suppl 1]: 1-266, 2002
35. Drüeke T: Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 16 [Suppl 7]: 25-28, 2001
36. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006 (Pubitemid 44749317)
37. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK: Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74: 791-798, 2008
38. Ishani A, Solid CA, Weinhandl ED, Gilbertson DT, Foley RN, Collins AJ: Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death. Nephrol Dial Transplant 23: 1682-1689, 2008 (Pubitemid 351767748)